# How to Turn Single-Cell Data Into a New Class of Cell-Depleting Therapies

Page: https://stenobird.com/podcast/data-in-biotech-6628050/how-to-turn-single-cell-data-into-a-new-class-of-cell-depleting-therapies
Text version: https://stenobird.com/podcast/data-in-biotech-6628050/how-to-turn-single-cell-data-into-a-new-class-of-cell-depleting-therapies.md
Podcast: [Data in Biotech](https://stenobird.com/podcast/data-in-biotech-6628050)
Published: 2026-08-19T17:00:25+00:00
Episode link: https://www.corrdyn.com/
Audio file: https://downloads.pod.co/5fac40cd-043b-485f-838d-c63fa01ae1b2/ae034d9e-1059-42ee-8541-a9ae3c787273.mp3
Processing state: not_requested
JSON: https://stenobird.com/v1/public/podcasts/data-in-biotech-6628050/episodes/how-to-turn-single-cell-data-into-a-new-class-of-cell-depleting-therapies
Duration seconds: 3252

## Resource

Why treating the cell, not the protein, could turn chronic disease treatment into something closer to a cure. You've built single-cell pipelines that spit out clusters, p-values and target lists, but nothing that survives contact with the clinic. What if the clustering method itself is quietly leading you astray? Adam Freund is Founder and CEO of Arda Therapeutics, a biotech using single-cell sequencing to find the pathogenic cells driving chronic disease. He spent seven years as a Principal Investigator at Calico Life Sciences, building a research lab on the biology of ageing and helping grow the company from 15 to more than 200 people, and holds a PhD in Molecular and Cell Biology from UC Berkeley. You'll get a working model for how Arda's discovery engine turns single-cell and spatial transcriptomic data into causal cell targets. Adam explains why a common statistical shortcut in single-cell analysis produces disease signals that don't hold up and how cell depletion could replace daily dosing with a handful of treatments that reset the immune system. Ross and Adam cover how Arda finds pathogenic cell populations across hundreds of donors, why chi-squared tests on cell clusters can substitute cell count for donor count without anyone noticing, and how B-cell depletion therapies proved that removing a cell can beat blocking its pathway. This one is for data science leaders and computational biologists building single-cell pipelines, not listeners after a general intro to drug discovery. Key Takeaways - Chi-squared tests on cell clusters draw their statistical power from the number of cells, not the number of donors, so a single oversampled patient can produce the same p-value as a hundred-donor study. - Rituximab clears 100% of B cells from circulation yet does nothin…

## Actions

- request_transcript: `POST https://stenobird.com/v1/public/podcasts/data-in-biotech-6628050/episodes/how-to-turn-single-cell-data-into-a-new-class-of-cell-depleting-therapies/transcription-requests` — Idempotently request low-priority transcript generation for this episode.
- read_markdown: `GET https://stenobird.com/podcast/data-in-biotech-6628050/how-to-turn-single-cell-data-into-a-new-class-of-cell-depleting-therapies.md` — Read the agent-friendly Markdown representation of this episode resource.

A page view does not enqueue transcription. Agents should invoke `request_transcript` explicitly when they need this episode processed.

## Transcript

Full transcripts are not published on public pages unless there is a clear rights basis.